生物技术公司ImmunityBio公布突破性临床数据，其研发的非化疗CD19靶向CAR-NK细胞疗法在治疗华氏巨球蛋白血症患者时，展现出持续15个月的持久性完全缓解。这一里程碑式成果标志着该疗法在血液肿瘤领域取得重大进展，为化疗不耐受患者提供了全新治疗选择。
临床观察显示，接受该疗法的患者不仅达到深度缓解状态，且在15个月随访期内未出现疾病复发迹象。与传统CAR-T疗法不同，此项疗法采用自然杀伤细胞作为载体，结合CD19靶向嵌合抗原受体技术，在避免化疗毒副作用的同时激活患者自身免疫系统。
该成果为B细胞恶性肿瘤的免疫治疗开辟了新路径，尤其对复发难治性华氏巨球蛋白血症患者具有重大临床意义。研究人员指出，持续15个月的完全缓解数据证实了该疗法持久的抗肿瘤活性，后续将开展更大规模临床试验验证其长期疗效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.